Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

I Mab (IMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow I Mab's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.800 -0.010    -0.55%
26/04 - Closed. Currency in USD ( Disclaimer )
  • Volume: 88,595
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.800 - 1.830
Type:  Equity
Market:  United States
I Mab 1.800 -0.010 -0.55%

I Mab Company Profile

 
Read the I Mab company profile to learn more about the business and the management team. View I Mab facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Contact Information

Address New Bund Center 55th Floor
555 West Haiyang Road Pudong District Shanghai, 200124
China
Phone 86 21 6057 8000
Fax -

Top Executives

Name Age Since Title
Xi Liu - 2021 Independent Director
Patricia LoRusso - 2019 Member of Scientific Advisory Board
Pamela M. Klein 63 2020 Interim Chairperson
Howard L. Weiner 77 2019 Member of Scientific Advisory Board
Timothy A. Yap 49 2019 Member of Scientific Advisory Board
Roy Steven Herbst 61 2019 Member of Scientific Advisory Board
Chia-Hung Yang 61 2020 Independent Director
Jun Ma - 2020 Member of Scientific Advisory Board
Wei Fu 42 2018 Director
Chun Kwok Au 51 2020 Independent Director
Rong Shao 62 2021 Independent Director
Yi-Long Wu - 2019 Member of Scientific Advisory Board
Chen Dong - 2020 Member of Scientific Advisory Board
Eric K. Rowinsky 67 2019 Member of Scientific Advisory Board
Ruyi He 62 2021 Independent Director
Raj Kannan 60 2023 CEO & Director
Shuai Chen 50 2023 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMAB Price Commentary

Write your thoughts about I Mab
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
KENNETH biden
KENNETH biden Jun 24, 2023 22:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hot weather = THIRST = DRINKS = HOLIDAYS = SPENDING MONEY = PROFIT = £ 2.23. Bought back in at : £ 2.034 ~ £ 2.234. 5000 x £ 0. 20 = £ 1,000 - £ 130 = £ 870 in three weeks?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email